O	0	6	Effect
O	7	9	of
B-intervention	10	19	Metformin
O	20	22	on
O	23	29	Breast
O	30	36	Ductal
O	37	46	Carcinoma
O	47	49	In
O	50	54	Situ
O	55	68	Proliferation
O	69	71	in
O	72	73	a
O	74	84	Randomized
O	85	96	Presurgical
O	97	102	Trial
O	102	103	.

O	104	113	Metformin
O	114	116	is
O	117	127	associated
O	128	132	with
O	133	138	lower
O	139	145	breast
O	146	152	cancer
O	153	157	risk
O	158	160	in
O	161	174	epidemiologic
O	175	182	studies
O	183	186	and
O	187	193	showed
O	194	203	decreased
O	204	217	proliferation
O	218	220	in
O	221	225	HER2
O	225	226	-
O	226	234	positive
O	235	241	breast
O	242	248	cancer
O	249	251	in
O	252	253	a
O	254	265	presurgical
O	266	271	trial
O	271	272	.

O	273	275	To
O	276	283	provide
O	284	291	insight
O	292	296	into
O	297	300	its
O	301	311	preventive
O	312	321	potential
O	321	322	,
O	323	325	we
O	326	334	measured
O	335	348	proliferation
O	349	351	by
O	352	354	Ki
O	354	355	-
O	355	357	67
O	358	366	labeling
O	367	372	index
O	373	374	(
O	374	376	LI
O	376	377	)
O	378	380	of
O	381	396	intraepithelial
O	397	404	lesions
O	405	416	surrounding
O	417	423	breast
O	424	430	cancer
O	430	431	.

O	432	434	We
O	435	443	randomly
O	444	452	assigned
B-total-participants	453	456	200
B-eligibility	457	468	nondiabetic
I-eligibility	469	477	patients
I-eligibility	478	487	diagnosed
I-eligibility	488	492	with
I-eligibility	493	501	invasive
I-eligibility	502	508	breast
I-eligibility	509	515	cancer
O	516	518	in
O	519	523	core
O	524	532	biopsies
O	533	535	to
O	536	545	metformin
O	545	546	,
O	547	548	1
O	548	549	,
O	549	552	700
O	553	555	mg
O	556	558	or
B-control	559	566	placebo
O	567	571	once
O	572	577	daily
O	578	581	for
O	582	584	28
O	585	589	days
O	590	596	before
O	597	604	surgery
O	604	605	.

O	606	610	Upon
O	611	618	surgery
O	618	619	,
O	620	624	five
O	625	627	to
O	628	633	seven
O	634	643	specimens
O	644	646	of
O	647	653	cancer
O	654	662	adjacent
O	663	664	(
O	664	665	â‰¤
O	665	666	1
O	667	669	cm
O	669	670	)
O	671	674	and
O	675	682	distant
O	683	684	(
O	684	685	>
O	685	686	1
O	687	689	cm
O	689	690	)
O	691	697	tissue
O	698	702	were
O	703	711	screened
O	712	715	for
O	716	720	LCIS
O	720	721	,
O	722	728	ductal
O	729	738	carcinoma
O	739	741	in
O	742	746	situ
O	747	748	(
O	748	752	DCIS
O	752	753	)
O	753	754	,
O	755	758	and
O	759	765	ductal
O	766	777	hyperplasia
O	778	779	(
O	779	781	DH
O	781	782	)
O	782	783	.

O	784	787	The
O	788	798	prevalence
O	799	801	of
O	802	806	LCIS
O	806	807	,
O	808	812	DCIS
O	812	813	,
O	814	817	and
O	818	820	DH
O	821	824	was
O	825	826	4
O	826	827	.
O	827	828	5
O	828	829	%
O	830	831	(
O	831	832	9
O	832	833	/
O	833	836	200
O	836	837	)
O	837	838	,
O	839	841	67
O	841	842	%
O	843	844	(
O	844	847	133
O	847	848	/
O	848	851	200
O	851	852	)
O	852	853	,
O	854	857	and
O	858	860	35
O	860	861	%
O	862	863	(
O	863	865	69
O	865	866	/
O	866	869	200
O	869	870	)
O	870	871	,
O	872	884	respectively
O	884	885	.

O	886	893	Overall
O	893	894	,
O	895	904	metformin
O	905	908	did
O	909	912	not
O	913	919	affect
O	920	922	Ki
O	922	923	-
O	923	925	67
O	926	928	LI
O	929	931	in
O	932	944	premalignant
O	945	954	disorders
O	954	955	.

O	956	959	The
B-outcome	960	966	median
I-outcome	967	980	posttreatment
I-outcome	981	983	Ki
I-outcome	983	984	-
I-outcome	984	986	67
I-outcome	987	989	LI
O	990	991	(
O	991	994	IQR
O	994	995	)
O	996	998	in
O	999	1002	the
O	1003	1012	metformin
O	1013	1016	and
O	1017	1024	placebo
O	1025	1028	arm
O	1029	1032	was
O	1032	1033	,
O	1034	1046	respectively
O	1046	1047	,
B-iv-cont-median	1048	1050	15
I-iv-cont-median	1050	1051	%
O	1052	1053	(
O	1053	1054	5
O	1054	1055	-
O	1055	1057	15
O	1057	1058	)
O	1059	1065	versus
B-cv-cont-median	1066	1067	5
I-cv-cont-median	1067	1068	%
O	1069	1070	(
O	1070	1071	4
O	1071	1072	-
O	1072	1073	6
O	1073	1074	)
B-outcome	1075	1077	in
I-outcome	1078	1082	LCIS
O	1083	1084	(
O	1084	1085	P
O	1086	1087	=
O	1088	1089	0
O	1089	1090	.
O	1090	1091	1
O	1091	1092	)
O	1092	1093	,
B-iv-cont-median	1094	1096	12
I-iv-cont-median	1096	1097	%
O	1098	1099	(
O	1099	1100	8
O	1100	1101	-
O	1101	1103	20
O	1103	1104	)
O	1105	1111	versus
B-cv-cont-median	1112	1114	10
I-cv-cont-median	1114	1115	%
O	1116	1117	(
O	1117	1118	7
O	1118	1119	-
O	1119	1121	24
O	1121	1122	)
B-outcome	1123	1125	in
I-outcome	1126	1130	DCIS
O	1131	1132	(
O	1132	1133	P
O	1134	1135	=
O	1136	1137	0
O	1137	1138	.
O	1138	1139	9
O	1139	1140	)
O	1140	1141	,
O	1142	1145	and
B-iv-cont-median	1146	1147	3
I-iv-cont-median	1147	1148	%
O	1149	1150	(
O	1150	1151	1
O	1151	1152	-
O	1152	1153	4
O	1153	1154	)
O	1155	1161	versus
B-cv-cont-median	1162	1163	3
I-cv-cont-median	1163	1164	%
O	1165	1166	(
O	1166	1167	1
O	1167	1168	-
O	1168	1169	4
O	1169	1170	)
B-outcome	1171	1173	in
I-outcome	1174	1176	DH
O	1177	1178	(
O	1178	1179	P
O	1180	1181	=
O	1182	1183	0
O	1183	1184	.
O	1184	1185	5
O	1185	1186	)
O	1186	1187	.

O	1188	1195	However
O	1195	1196	,
B-outcome	1197	1210	posttreatment
I-outcome	1211	1213	Ki
I-outcome	1213	1214	-
I-outcome	1214	1216	67
I-outcome	1217	1219	in
I-outcome	1220	1224	HER2
I-outcome	1224	1225	-
I-outcome	1225	1233	positive
I-outcome	1234	1238	DCIS
I-outcome	1239	1246	lesions
O	1247	1250	was
O	1251	1264	significantly
O	1265	1270	lower
O	1271	1273	in
O	1274	1279	women
O	1280	1290	randomized
O	1291	1293	to
O	1294	1303	metformin
O	1304	1314	especially
O	1315	1319	when
O	1320	1322	ER
O	1323	1326	was
O	1327	1338	coexpressed
O	1338	1339	:
B-iv-cont-median	1340	1342	22
I-iv-cont-median	1342	1343	%
O	1344	1345	(
O	1345	1347	11
O	1347	1348	-
O	1348	1350	32
O	1350	1351	)
O	1352	1358	versus
B-cv-cont-median	1359	1361	35
I-cv-cont-median	1361	1362	%
O	1363	1364	(
O	1364	1366	30
O	1366	1367	-
O	1367	1369	40
O	1369	1370	)
B-outcome	1371	1373	in
I-outcome	1374	1378	HER2
I-outcome	1378	1379	-
I-outcome	1379	1387	positive
I-outcome	1388	1392	DCIS
O	1393	1394	(
O	1394	1395	n
O	1396	1397	=
O	1398	1400	22
O	1400	1401	,
O	1402	1403	P
O	1404	1405	=
O	1406	1407	.
O	1407	1409	06
O	1409	1410	)
O	1410	1411	;
B-iv-cont-median	1412	1414	12
I-iv-cont-median	1414	1415	%
O	1416	1417	(
O	1417	1418	7
O	1418	1419	-
O	1419	1421	18
O	1421	1422	)
O	1423	1429	versus
B-cv-cont-median	1430	1432	32
I-cv-cont-median	1432	1433	%
O	1434	1435	(
O	1435	1437	27
O	1437	1438	-
O	1438	1440	42
O	1440	1441	)
B-outcome	1442	1444	in
I-outcome	1445	1447	ER
I-outcome	1447	1448	-
I-outcome	1448	1456	positive
I-outcome	1456	1457	/
I-outcome	1457	1461	HER2
I-outcome	1461	1462	-
I-outcome	1462	1470	positive
I-outcome	1471	1475	DCIS
O	1476	1477	(
O	1477	1478	n
O	1479	1480	=
O	1481	1483	15
O	1483	1484	,
O	1485	1486	P
O	1487	1488	=
O	1489	1490	.
O	1490	1493	004
O	1493	1494	)
O	1494	1495	.

O	1496	1501	Eight
O	1502	1504	of
O	1505	1507	22
O	1508	1509	(
O	1509	1511	36
O	1511	1512	%
O	1512	1513	)
O	1514	1518	HER2
O	1518	1519	-
O	1519	1527	positive
O	1528	1532	DCIS
O	1533	1537	were
O	1538	1546	adjacent
O	1547	1549	to
O	1550	1554	HER2
O	1554	1555	-
O	1555	1563	negative
B-outcome	1564	1572	invasive
I-outcome	1573	1579	breast
I-outcome	1580	1586	cancer
O	1586	1587	.

O	1588	1590	In
O	1591	1597	tissue
O	1598	1605	samples
O	1606	1614	obtained
O	1615	1624	following
O	1625	1626	4
O	1627	1632	weeks
O	1633	1635	of
O	1636	1641	study
O	1642	1646	drug
O	1646	1647	,
O	1648	1661	proliferation
O	1662	1665	was
O	1666	1671	lower
O	1672	1674	in
O	1675	1679	HER2
O	1679	1680	-
O	1680	1688	positive
O	1689	1693	DCIS
O	1694	1697	for
O	1698	1703	women
O	1704	1714	randomized
O	1715	1717	to
O	1718	1727	metformin
O	1728	1734	versus
O	1735	1742	placebo
O	1742	1743	.

O	1744	1746	An
O	1747	1755	adjuvant
O	1756	1761	trial
O	1762	1775	incorporating
O	1776	1785	metformin
O	1786	1788	in
O	1789	1793	HER2
O	1793	1794	-
O	1794	1802	positive
O	1803	1807	DCIS
O	1808	1810	is
O	1811	1820	warranted
O	1820	1821	.
